TY - JOUR
T1 - The psychiatric effects of ketogenic diet therapy on adults with chronic epilepsy
AU - Shegelman, Abigail
AU - Carson, Kathryn A.
AU - McDonald, Tanya J.W.
AU - Henry-Barron, Bobbie J.
AU - Diaz-Arias, Luisa A.
AU - Cervenka, Mackenzie C.
N1 - Funding Information:
The authors would like to acknowledge patients who participated in the study, Johns Hopkins Adult Epilepsy Diet Center Medical Office Coordinators Joanne Barnett and Corri Woodland, dietitians Diane Vizthum, Haley Schlechter, and nurse Rebecca Fisher. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Support for statistical analysis was made possible by The Johns Hopkins Institute for Clinical and Translational Research, funded in part by [Grant Number UL1 TR003098] the National Center for Advancing Translational Sciences, a component of the National Institutes of Health. Abigail Shegelman MHS has no conflicts of interest to disclose. Mackenzie C. Cervenka, MD Disclosures: The author has received support from The Epilepsy Foundation, The Johns Hopkins University School of Medicine Clinician Scientist Award, Nutricia, Vitaflo, The Glut1 Deficiency Foundation, The Carson Harris Foundation, Owens Family Foundation, Elaine Freeman and Johns Hopkins University Department of Neurosurgery, NIH (NINDS R01NS075020), and Army Research Laboratory. Dr. Cervenka has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Nutricia North America and The Glut1 Deficiency Foundation. Dr. Cervenka has received research support from Nutricia North America and Vitaflo. Dr. Cervenka receives royalties from Springer Publishing Company. Tanya J. W. McDonald MD PhD has received personal compensation for speaking activities with Nutricia North America. The author has received support from the Johns Hopkins KL2 Mentored Career Development Award. Kathryn A. Carson has no conflicts of interest to disclose. Bobbie J. Henry-Barron, RD, LDN Disclosure: The author has received support from The Johns Hopkins Institute for Clinical and Translational Research (ICTR), funded in part by NIH grants (UL1 TR TR003098 NCATS), NIH Roadmap for Medical Research, Nutricia, Vitaflo, and The Carson Harris Foundation. Bobbie Henry-Barron has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Nutricia, BioMarin, and Therachon. Luisa A. Diaz-Arias, MD has no conflicts of interest to disclose.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/4
Y1 - 2021/4
N2 - Objectives: Patients with epilepsy are known to exhibit high rates of comorbid psychiatric disorders such as depression, anxiety, and other mood disorders. Little is known about the psychiatric effects of a ketogenic diet therapy (KDT) on adults with epilepsy. The objective of this study was to better understand the relationship between KDT and psychological state based on depressive and anxiety symptoms in adults with chronic epilepsy. Methods: Adults at the Johns Hopkins Adult Epilepsy Diet Center on a modified Atkins diet (MAD) for at least one month were surveyed retrospectively. Adults who were diet naïve were given a baseline survey and an additional survey after 3 months or more on MAD. Surveys included validated measures of depressive and anxiety symptoms as well as their severity. Participant demographics, seizure frequency, and use of concomitant antiseizure drugs (ASDs), chronic anxiolytics (excluding as-needed benzodiazepines for seizure rescue only), and/or antidepressant drugs were extracted from electronic medical records. Results: One-hundred participants aged 19–75 enrolled in the study. Sixty participants filled out a single retrospective survey. Of 40 diet naïve participants who filled out a baseline prospective survey, 19 completed a follow-up survey while on MAD and 21 participants were lost to follow-up. Longer diet duration was significantly associated with fewer anxiety and depressive symptoms, based on psychiatric measure scores, in retrospective study participants. Lower seizure frequency was also significantly associated with less anxiety symptoms in the retrospective cohort. Prospective study participants did not experience significant change in anxiety or depressive symptoms on the diet. There was a significant correlation between higher ketone level and responder rate (≥50% seizure reduction) in the prospective cohort, although no correlation between ketone level and change in psychiatric symptoms was seen. Significance: Psychiatric comorbidity among patients with epilepsy is quite common and can be influenced by multiple factors such as seizure frequency, the use of various ASDs, social factors, and underlying etiology. Although ketogenic diet therapies have been in clinical use for one century, the psychiatric impacts have been insufficiently explored. This study provides preliminary evidence that KDT may have a positive impact on psychological state independent of seizure reduction or ketone body production and may be influenced by longer duration of diet therapy. These results support further investigation into specific effects and potential therapeutic benefits on various psychiatric disorders.
AB - Objectives: Patients with epilepsy are known to exhibit high rates of comorbid psychiatric disorders such as depression, anxiety, and other mood disorders. Little is known about the psychiatric effects of a ketogenic diet therapy (KDT) on adults with epilepsy. The objective of this study was to better understand the relationship between KDT and psychological state based on depressive and anxiety symptoms in adults with chronic epilepsy. Methods: Adults at the Johns Hopkins Adult Epilepsy Diet Center on a modified Atkins diet (MAD) for at least one month were surveyed retrospectively. Adults who were diet naïve were given a baseline survey and an additional survey after 3 months or more on MAD. Surveys included validated measures of depressive and anxiety symptoms as well as their severity. Participant demographics, seizure frequency, and use of concomitant antiseizure drugs (ASDs), chronic anxiolytics (excluding as-needed benzodiazepines for seizure rescue only), and/or antidepressant drugs were extracted from electronic medical records. Results: One-hundred participants aged 19–75 enrolled in the study. Sixty participants filled out a single retrospective survey. Of 40 diet naïve participants who filled out a baseline prospective survey, 19 completed a follow-up survey while on MAD and 21 participants were lost to follow-up. Longer diet duration was significantly associated with fewer anxiety and depressive symptoms, based on psychiatric measure scores, in retrospective study participants. Lower seizure frequency was also significantly associated with less anxiety symptoms in the retrospective cohort. Prospective study participants did not experience significant change in anxiety or depressive symptoms on the diet. There was a significant correlation between higher ketone level and responder rate (≥50% seizure reduction) in the prospective cohort, although no correlation between ketone level and change in psychiatric symptoms was seen. Significance: Psychiatric comorbidity among patients with epilepsy is quite common and can be influenced by multiple factors such as seizure frequency, the use of various ASDs, social factors, and underlying etiology. Although ketogenic diet therapies have been in clinical use for one century, the psychiatric impacts have been insufficiently explored. This study provides preliminary evidence that KDT may have a positive impact on psychological state independent of seizure reduction or ketone body production and may be influenced by longer duration of diet therapy. These results support further investigation into specific effects and potential therapeutic benefits on various psychiatric disorders.
KW - Anxiety
KW - Depression
KW - Epilepsy
KW - Ketogenic
KW - Modified Atkins
KW - Psychiatric disorder
UR - http://www.scopus.com/inward/record.url?scp=85101309543&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101309543&partnerID=8YFLogxK
U2 - 10.1016/j.yebeh.2021.107807
DO - 10.1016/j.yebeh.2021.107807
M3 - Article
C2 - 33610104
AN - SCOPUS:85101309543
SN - 1525-5050
VL - 117
JO - Epilepsy and Behavior
JF - Epilepsy and Behavior
M1 - 107807
ER -